Deodhar S D, Lee V W, Chiang T, Mahmoud A F, Watten K S
Cancer Res. 1976 Sep;36(9 pt.1):3147-50.
In both isogeneic (Sarcoma 1 in A/JAX mice) and allogeneic (Sarcoma 180 in C57BL/6 mice) mouse tumor systems, treatment of the tumor-bearing mice with niridazole, an antiprarasitic drug, known to be a potent suppressor of cell mediated but not humoral immunity caused enhancement of metastases to regional popliteal nodes. Niridazole also inhibited tumor growth in vivo, as manifested by a significant decrease in the weight of the primary tumors. The enhancement of metastases is attributed to the suppression of cell-mediated immunity by the drug, but the mechanism of tumor-growth inhibition is not yet clear.
在同基因（A/JAX小鼠中的肉瘤1）和异基因（C57BL/6小鼠中的肉瘤180）小鼠肿瘤系统中，用硝咪唑（一种抗寄生虫药物，已知是细胞介导免疫而非体液免疫的有效抑制剂）处理荷瘤小鼠，导致转移至局部腘淋巴结的情况增加。硝咪唑还在体内抑制肿瘤生长，表现为原发性肿瘤重量显著减轻。转移增加归因于该药物对细胞介导免疫的抑制，但肿瘤生长抑制的机制尚不清楚。
